Calciphylaxis: No therapeutic concepts for a poorly understood syndrome?;Kalziphylaxie: Keine therapeutischen konzepte für ein wenig verstandenes syndrom?

JDDG - Journal of the German Society of Dermatology

Volumn 4, Issue 12, 2006, Pages 1037-1044

  Meissner, Markus ^a   Gille, Jens ^a   Kaufmann, Roland ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Calciphylaxis; Calcium; Necrosis; Phosphate; Sodium thiosulfate; Ulcers

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; BISPHOSPHONIC ACID DERIVATIVE; CALCIMIMETIC AGENT; CALCIUM DERIVATIVE; CINACALCET; COLECALCIFEROL DERIVATIVE; HEPARIN; INSULIN; LOW MOLECULAR WEIGHT HEPARIN; PHENPROCOUMON; SEVELAMER; SODIUM THIOSULFATE; WARFARIN;

ADIPOSE TISSUE; CALCINOSIS; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATALITY; HUMAN; HYPERBARIC OXYGEN; INJURY; ISCHEMIA; MORTALITY; PAIN; PARATHYROIDECTOMY; PATHOGENESIS; RECURRENT INFECTION; REVIEW; RISK ASSESSMENT; SECONDARY HYPERPARATHYROIDISM; SEPSIS; SKIN NECROSIS; SUBCUTANEOUS TISSUE; SYSTEMATIC REVIEW; TREATMENT INDICATION; WOUND CARE;

AGE FACTORS; CALCIPHYLAXIS; CALCIUM; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERBARIC OXYGENATION; HYPERPARATHYROIDISM; INCIDENCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NAPHTHALENES; OBESITY; PARATHYROIDECTOMY; PHOSPHATES; RENAL DIALYSIS; RISK FACTORS; SEX FACTORS; THIOSULFATES; TIME FACTORS;

EID: 33845610425     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2006.06127.x     Document Type: Review

References (51)

1. Bryant JH, White WH. A case of calcification of the arteries and obliterative endarteritis, associated with hydronephrosis, in a child aged six months. Guys Hospital Rep 1898; 55: 17-20.
2. Gipstein RM, Coburn JW, Adams DA, Lee DB, Parsa KP, Sellers A, Suki WN, Massry SG. Calciphylaxis in man. A syndrome of tissue necrosis and vascular calcification in 11 patients with chronic renal failure. Arch Intern Med 1976;136 (11): 1273-80.
3. Selye H, Gabbiani G, Strebel R. Sensitization to calciphylaxis by endogenous parathyroid hormone. Endocrinology 1962; 71: 554-8.
4. Selye H, Goldie I, Strebel R. Calciphylaxis in relation to calcification in periarticular tissues. Clin Orthop Relat Res 1963; 28: 181-92.
5. Angelis M, Wong LL, Myers SA, Wong LM. Calciphylaxis in patients on hemodialysis: a prevalence study. Surgery 1997;122 (6): 1083-9.
6. Mastruserio DN, Nguyen EQ, Nielsen T, Hessel A, Pellegrini AE. Calciphylaxis associated with metastatic breast carcinoma. J Am Acad Dermatol 1999;41 (2 Pt 2): 295-8.
7. Barri YM, Graves GS, Knochel JP. Calciphylaxis in a patient with Crohn's disease in the absence of end-stage renal disease. Am J Kidney Dis 1997; 29 (5): 773-6.
8. Ferreres J, Marcoval J, Bordas X, Moreno A, Muniesa C, Prat C, Peyri J. Calciphylaxis associated with alcoholic cirrhosis. J Eur Acad Dermatol Venereol 2006; 20 (5): 599-601.
9. Pollock B, Cunliffe WJ, Merchant WJ. Calciphylaxis in the absence of renal failure. Clin Exp Dermatol 2000; 25 (5): 389-92.
10. Hafner J, Keusch G, Wahl C, Burg G. Calciphylaxis: a syndrome of skin necrosis and acral gangrene in chronic renal failure. Vasa 1998; 27 (3): 137-43.
11. Wilmer WA, Magro CM. Calciphylaxis: emerging concepts in prevention, diagnosis, and treatment. Semin Dial 2002; 15 (3): 172-86.
12. Matsuo T, Tsukamoto Y, Tamura M, Hanaoka M, Nagaoka T, Kobayashi Y, Higashihara M, Yokoyama H, Saegusa N. Acute respiratory failure due to "pulmonary calciphylaxis" in a maintenance haemodialysis patient. Nephron 2001; 87 (1): 75-9.
13. Schmidt H, Creutzfeldt W. Calciphylactic pancreatitis and pancreatitis in hyperparathyroidism. Clin Orthop Relat Res 1970; 69: 135-45.
14. Randall DP, Fisher MA, Thomas C. Rhabdomyolysis as the presenting manifestation of calciphylaxis. Muscle Nerve. 2000; 23 (2): 289-93.
15. Essary LR, Wick MR. Cutaneous calciphylaxis. An underrecognized clinicopathologic entity. Am J Clin Pathol 2000; 113 (2): 280-7.
16. Ledbetter LS, Khoshnevis MR, Hsu S. Calciphylaxis. Cutis 2000; 66 (1): 49-51.
17. Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Muller-Esterl W, Schinke T, Jahnen-Dechent W. The serum protein alpha 2-Heremans-Schmid glycoprotein/-fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003; 112 (3): 357-66.
18. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997; 386 (6620): 78-81.
19. Ahmed S, O'Neill KD, Hood AF, Evan AP, Moe SM. Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. Am J Kidney Dis 2001; 37 (6): 1267-76.
20. Moe SM, O'Neill KD, Duan D, Ahmed S, Chen NX, Leapman SB, Fineberg N, Kopecky K. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 2002; 61 (2): 638-47.
21. Moe SM, Duan D, Doehle BP, O'Neill KD, Chen NX. Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int 2003; 63 (3): 1003-11.
22. Jono S, Peinado C, Giachelli CM. Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification. J Biol Chem 2000 30; 275 (26): 20197-203.
23. Steitz SA, Speer MY, Curinga G, Yang HY, Haynes P, Aebersold R, Schinke T, Karsenty G, Giachelli CM. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 2001 7; 89 (12): 1147-54.
24. Price PA, Caputo JM, Williamson MK. Bone origin of the serum complex of calcium, phosphate, fetuin, and matrix Gla protein: biochemical evidence for the cancellous bone-remodeling compartment. J Bone Miner Res 2002; 17 (7): 1171-9.
25. Proudfoot D, Skepper JN, Hegyi L, Bennett MR, Shanahan CM, Weissberg PL. Apoptosis regulates human vascular calcification in vitro: evidence for initiation of vascular calcification by apoptotic bodies. Circ Res 2000; 87 (11): 1055-62.
26. Hayden MR, Tyagi SC, Kolb L, Sowers JR, Khanna R. Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. Cardiovasc Diabetol 2005; 4 (1): 4.
27. Mazhar AR, Johnson RJ, Gillen D, Stivelman JC, Ryan MJ, Davis CL, Stehman-Breen CO. Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int 2001; 60 (1): 324-32.
28. Zacharias JM, Fontaine B, Fine A. Calcium use increases risk of calciphylaxis: a case-control study. Perit Dial Int 1999; 19 (3): 248-52.
29. Block GA. Prevalence and clinical consequences of elevated Ca X P product in hemodialysis patients. Clin Nephrol 2000; 54 (4): 318-24.
30. Bleyer AJ, Choi M, Igwemezie B, de la Torre E, White WL. A case control study of proximal calciphylaxis. Am J Kidney Dis. 1998; 32 (3): 376-83.
31. Summers LK, Samra JS, Humphreys SM, Morris RJ, Frayn KN. Subcutaneous abdominal adipose tissue blood flow: variation within and between subjects and relationship to obesity. Clin Sci (Lond) 1996; 91 (6): 679-83.
32. Janigan DT, Perey B, Marrie TJ, Chiasson PM, Hirsch D. Skin necrosis: an unusual complication of hyperphosphatemia during total parenteral nutrition therapy. JPEN J Parenter Enteral Nutr 1997; 21 (1): 50-2.
33. Wilmer WA, Voroshilova O, Singh I, Middendorf DF, Cosio FG. Transcutaneous oxygen tension in patients with calciphylaxis. Am J Kidney Dis 2001; 37 (4): 797-806.
34. Duffy A, Schurr M, Warner T, Chen H. Long-term outcomes in patients with calciphylaxis from hyperparathyroidism. Ann Surg Oncol 2006; 13 (1): 96-102.
35. Kang AS, McCarthy JT, Rowland C, Farley DR, van Heerden JA. Is calciphylaxis best treated surgically or medically? Surgery 2000; 128 (6): 967-71.
36. Chavel SM, Taraszka KS, Schaffer JV, Lazova R, Schechner JS. Calciphylaxis associated with acute, reversible renal failure in the setting of alcoholic cirrhosis. J Am Acad Dermatol 2004; 50 (5 Suppl): S125-8.
37. Price PA, Faus SA, Williamson MK. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler Thromb Vasc Biol 1998; 18 (9): 1400-7.
38. Wallin R, Cain D, Sane DC. Matrix Gla protein synthesis and gamma-carboxylation in the aortic vessel wall and proliferating vascular smooth muscle cells - a cell system which resembles the system in bone cells. Thromb Haemost 1999; 82 (6): 1764-7.
39. Coates T, Kirkland GS, Dymock RB, Murphy BF, Brealey JK, Mathew TH, Disney AP. Cutaneous necrosis from calcific uremic arteriolopathy. Am J Kidney Dis 1998; 32 (3): 384-91.
40. Beddhu S. The body mass index paradox and an obesity, inflammation, and atherosclerosis syndrome in chronic kidney disease. Semin Dial 2004;17 (3):229-32.
41. Goldsmith DJ, Covic A, Sambrook PA, Ackrill P. Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis. Nephron 1997; 77 (1): 37-43.
42. Norris B, Vaysman V, Line BR. Bone scintigraphy of calciphylaxis: a syndrome of vascular calcification and skin necrosis. Clin Nucl Med 2005; 30 (11): 725-7.
43. Lipsker D, Chosidow O, Martinez F, Challier E, Frances C. Low-calcium dialysis in calciphylaxis. Arch Dermatol 1997; 133 (6): 798-9.
44. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000; 35 (6): 1226-37.
45. Velasco N, Macgregor MS, Innes A, Mackay IG. Successful treatment of calciphylaxis with cinacalcet - an alternative to parathyroidectomy? Nephrol Dial Transplant 2006; 21 (7): 1999-2004.
46. Green JA, Green CR, Minott SD. Calciphylaxis treated with neurolytic lumbar sympathetic block: case report and review of the literature. Reg Anesth Pain Med 2000; 25 (3): 310-2.
47. Basile C, Montanaro A, Masi M, Pati G, De Maio P, Gismondi A. Hyperbaric oxygen therapy for calcific uremic arteriolopathy: a case series. J Nephrol 2002; 15 (6): 676-80.
48. Yatzidis H. Successful sodium thiosulphate treatment for recurrent calcium urolithiasis. Clin Nephrol 1985; 23 (2): 63-7.
49. Agroyannis BJ, Koutsikos DK, Tzanatos HA, Konstadinidou IK. Sodium thiosulphate in the treatment of renal tubular acidosis I with nephrocalcinosis. Scand J Urol Nephrol 1994; 28 (1): 107-8.
50. Cicone JS, Petronis JB, Embert CD, Spector DA. Successful treatment of calciphylaxis with intravenous sodium thiosulfate. Am J Kidney Dis 2004; 43 (6): 1104-8.
51. Meissner M, Bauer R, Beier C, Betz C, Wolter M, Kaufmann R, Gille J. Sodium thiosulphate as a promising therapeutic option to treat calciphylaxis. Dermatology 2006; 212: 373-376.